The Patient Journey in Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Therapies: Qualitative Insights Using a Global Ethnographic Approach
- 246 Downloads
The advent and approval of tyrosine kinase inhibitors (TKIs) have dramatically improved the life expectancy of patients with chronic myeloid leukemia (CML), which has been transformed into a chronically manageable disease.
The objective was to qualitatively assess the effects of diagnosis and treatment on patients with CML to offer recommendations for health-care providers (HCPs) for the better support of patients.
By use of an ethnographic approach based on in-home interviews, photo journals, and an optional telephone debriefing interview, this study included 50 patients with CML from Brazil, France, Germany, Russia, and Spain, including patients within 18 months of diagnosis and receiving frontline TKI therapy (n = 20), patients between >18 months and 7 years from diagnosis and receiving ongoing frontline therapy (n = 20), and patients who switched to second- or third-line TKI therapy (n = 10). In-home interviews were designed to address patient perceptions and experiences regarding such issues as adherence, disease knowledge, disease management, and relationships with HCPs. Transcripts from these interviews and other data were analyzed to identify similar patterns and themes experienced by patients with CML.
The investigation generated a five-stage, patient-centered model of the experience of the patient throughout diagnosis, treatment, and management of CML: crisis, hope, adaptation, new normal, and uncertainty. Patients proceeded through these stages in the course of their disease management. The stages were affected by the patients’ emotional and social experiences, their knowledge about CML, their positive experiences with their HCPs and/or treatment, and their optimism about their long-term prognosis.
We identified five common stages experienced by patients with CML and suggest several recommendations for HCPs on the management of patients through their disease journey. By providing support, education, and reassurance, HCPs can help patients as they move through the early stages of crisis and hope. When patients are in the adaptation and new-normal stages, HCPs can help patients achieve and maintain a new normality by setting expectations for the risks/benefits of long-term chronic drug therapy and disease monitoring and by continuing to support patient adherence.
KeywordsImatinib Chronic Myeloid Leukemia Dasatinib Nilotinib Normal Stage
This study was supported by Novartis Pharmaceuticals Corporation and conducted by Nancy Macdonald and Ari Shapiro while employed by Hall & Partners Healthcare. François Guilhot acted as a consultant for and received honoraria from Novartis Pharmaceuticals. John Coombs and Tomasz Szczudlo are employees and shareholders of Novartis Pharmaceuticals. Oleg Zernovak and Marc Paolantonio were employees of Novartis Pharmaceuticals at the time the research was conducted. Christina Bender is an employee of Novartis Pharmaceuticals. Nancy J. Macdonald has nothing to disclose. Ari Shapiro received funding for this research. Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals. We thank Nicole Parker, PhD, and Candice L. Willmon, PhD, for medical editorial assistance with this manuscript.
- 4.Hochhaus A, Shah NP, Cortes JE, et al. Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up. ASCO Meeting Abstracts. 2012;30(15 suppl):417s.Google Scholar
- 6.Botteman MF, Stephens J, Coombs J. Projecting the long-term survival of newly diagnosed patients with chronic myeloid leukemia (CML) in chronic phase (CP) receiving nilotinib or imatinib. Haematologica. 2010;95(s2):348.Google Scholar
- 7.Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28–37.CrossRefGoogle Scholar
- 9.National Comprehensive Cancer Network. Chronic myelogenous leukemia. NCCN Clinical Practice Guidelines in Oncology 2012; v.1. 2013.Google Scholar
- 12.Atkinson P, Hammersley M. Ethnography and participant observation. In: Denzin NK, Lincoln YS, editors. Handbook of qualitative research. Thousand Oaks: Sage Publications, Inc.; 1994. p. 248–61.Google Scholar
- 24.Guilhot F, Coombs J, Zernovak O, et al. A global retrospective and physician-based analysis of adherence to tyrosine kinase inhibitor (TKI) therapies for chronic myeloid leukemia (CML). Blood. 2010;116(21):644.Google Scholar
- 29.Folkman S, Lazarus RS. Manual for the Ways of Coping Questionnaire. Palo Alto: Counseling Psychological Press; 1988.Google Scholar